---
layout: post
title: "中国mRNA疫苗有望年底前取得有效率数据"
date: 2021-09-02T08:37:55.026Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20210902-1189498
tags: [ 联合早报 ]
categories: [ 联合早报 ]
---
<!--1630594800000-->
[中国mRNA疫苗有望年底前取得有效率数据](https://www.zaobao.com/realtime/china/story20210902-1189498)
------

<div>
<p>开发中国首款国产信使核糖核酸（mRNA）冠病疫苗的公司，希望在年底前获得疫苗后期试验的有效率数据，那将是中国在这一先进技术领域追赶西方的关键一步。</p><p>据彭博社报道，这种候选疫苗由云南沃森生物技术股份有限公司、苏州艾博生物科技有限公司和中国军队的科研人员合作开发。沃森生物副董事长黄镇在接受采访时介绍，疫苗已经在印尼和墨西哥获得了开展三期临床试验的批准。</p><p>黄镇说，他相信结果将与BNT疫苗（辉瑞-BioNTech）一致。BNT疫苗目前在包括美国在内的西方广泛使用，在三期试验中对有症状的新冠感染高度有效，对抗新冠病毒德尔塔(delta)变体的效果也很好。</p><section id="imu"><div id="dfp-ad-imu1">        </div></section><p>黄镇说，如果幸运的话，可以在一两个月后得出结果，否则可能要花上三四个月。“我们向前迈出了一步，这是一个艰难的旅程。”<br> </p>      <div id="innity-in-post"></div><div id="dfp-ad-midarticlespecial">        </div>      <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-desktop lazyload  " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" alt style="width:100%;" pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_desktop-zbpe399_2.png?dHEiGouxxZpWwWTJE04dyGyUN74JOU2z" referrerpolicy="no-referrer"></a>      <a href="https://subscribe.sph.com.sg/promotions/zbpe-3-months-99-cents-promotion/?utm_campaign=zbpe399&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-mobile lazyload " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" alt pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210901/paywall_mobile-zbpe399_2.png?qZnBcIGCJvPR8A2IAZOZuOxdoGZDatiI" referrerpolicy="no-referrer"></a>
</div>
